Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MKC-1 + Pemetrexed in Advanced Solid Tumors and NSCLC
NCT00408226Phase 2Completed
- Sponsor
- CASI Pharmaceuticals, Inc.
- Start
- Oct 2006
- Primary completion
- Jun 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mkc-1 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by CASI Pharmaceuticals, Inc. Primary endpoint: Occurrence of treatment emergent Adverse Events. Started Oct 2006; status: completed.
02
Drugs
mkc-1
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00408226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00408226.